Kocaman, GulsenKahraman, NeseGurkan Koseoglu, BanuBilgic, BasarMatur, ZelihaErtas, MustafaGulsen, YesimBaykan Baykal, Betul2020-10-222020-10-222018-12-01Kocaman G., Kahraman N., Gurkan Koseoglu B., Bilgic B., Matur Z., Ertas M., Gulsen Y., Baykan Baykal B., -Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders-, NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.55, ss.330-336, 2018http://hdl.handle.net/20.500.12645/24586Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD.ArticleWOS:0004566073000088506008943510.5152/npa.2017.1925730622389DOI: https://doi.org/10.5152/npa.2017.19257